Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a market capitalization of $7.65 million, announced new preclinical data for its therapeutic candidate PORT-7 at the European Lung Cancer Congress in Paris. The data revealed that PORT-7, when used alone and in combination with an anti-PD1 antibody, significantly inhibited tumor growth in a mesothelioma murine model. The company maintains a strong liquidity position with a current ratio of 3.08, indicating sufficient resources to fund its research initiatives.
The company’s presentation highlighted that PORT-7, a selective Adenosine A2B receptor inhibitor, demonstrated a single-agent activity and achieved more than 90% tumor growth inhibition when combined with an anti-PD1 antibody. Immunohistochemistry tests showed substantial infiltration of CD3 and CD45 positive immune cells within the tumors.
Mesothelioma, a type of aggressive cancer commonly linked to asbestos exposure, currently has limited treatment options. According to Portage, this is the first instance of a selective A2B receptor inhibitor showing anti-tumor activity against mesothelioma.
Portage is preparing to initiate a first-in-human clinical trial with PORT-7. Moreover, the company is advancing the dose escalation of PORT-6, another selective inhibitor targeting the A2A adenosine receptor. The strategic plan includes co-administering PORT-6 with PORT-7 in the ongoing ADPORT-601 trial, marking the first combination of A2A and A2B antagonists in patients. This approach aims to counteract adenosine-induced immunosuppression in the tumor microenvironment, potentially enhancing the efficacy of immunotherapy for solid tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.